Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer

Trial Profile

Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirapazamine (Primary)
  • Indications Carcinoma; Liver cancer; Liver metastases; Neuroendocrine tumours; Solid tumours
  • Focus First in man; Therapeutic Use
  • Sponsors Teclison
  • Most Recent Events

    • 19 Sep 2023 Primary endpoint has been amended and trial focus has been shifted to Tu, Age criteria of patient inclusion has been changed (20 to 99 year), Planned number of patients changed from 50 to 25.
    • 19 Sep 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
    • 19 Sep 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top